Development asset linked to CuraTeQ Biologics s.r.o in public FDA and regional records.
pharma · wet macula degeneration · Chronic Urticaria
CuraTeQ Biologics s.r.o
CuraTeQ Biologics s.r.o drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Hyderabad, IN HQ
2016 Founded
645 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Hyderabad, IN
- Founded
- 2016
- Employees
- 645
- Programs
- 2
- Drugs
- 6
- Patents
- 0
CuraTeQ Biologics s.r.o pipeline
Portfolio lens on 6 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
CuraTeQ Biologics s.r.o drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
omalizumab
Respiratory system (R03)US regulatory status: approved. Molecular target: Immunoglobulin heavy constant epsilon.
- Target
- Immunoglobulin heavy constant epsilon
- Mechanism
- Ig epsilon chain C region inhibitor
-
Development asset linked to CuraTeQ Biologics s.r.o in public FDA and regional records.
-
ranibizumab
Sensory organs (S01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.
- Target
- Vascular endothelial growth factor A, long form
- Mechanism
- Vascular endothelial growth factor A inhibitor
-
Development asset linked to CuraTeQ Biologics s.r.o in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor